These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8052700)

  • 41. Effect of L-buthionine sulfoximine on the radiation response of human renal carcinoma cell lines.
    Leung SW; Mitchell JB; al-Nabulsi I; Friedman N; Newsome J; Belldegrun A; Kasid U
    Cancer; 1993 Apr; 71(7):2276-85. PubMed ID: 8095848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Radioresistant subline of human glioma cell line MGR2R induced by repeated high dose X-ray irradiation].
    Cheng JJ; Hu Z; Xia YF; Chen ZP
    Ai Zheng; 2006 Jan; 25(1):45-50. PubMed ID: 16405748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
    Lee FY; Sciandra J; Siemann DW
    Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A diffusible resistance factor(s) in spontaneous mitomycin resistant mammalian cancer cells.
    Wan ZG; Kobayashi H; Hayakawa A; Ishigaki T
    Nagoya J Med Sci; 1998 May; 61(1-2):37-45. PubMed ID: 9664765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse.
    Chen YJ; Liao HF; Tsai TH; Wang SY; Shiao MS
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1252-61. PubMed ID: 16253780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.
    O'Dwyer PJ; Hamilton TC; Yao KS; Tew KD; Ozols RF
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):383-96. PubMed ID: 7642469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
    Friedman HS; Skapek SX; Colvin OM; Elion GB; Blum MR; Savina PM; Hilton J; Schold SC; Kurtzberg J; Bigner DD
    Cancer Res; 1988 Oct; 48(19):5397-402. PubMed ID: 3416297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
    Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
    Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs.
    Alaoui-Jamali M; Loubaba BB; Robyn S; Tapiero H; Batist G
    Cancer Chemother Pharmacol; 1994; 34(2):153-8. PubMed ID: 8194166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines.
    Batist G; Schecter R; Woo A; Greene D; Lehnert S
    Biochem Pharmacol; 1991 Feb; 41(4):631-5. PubMed ID: 1997009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ
    Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
    Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract]   [Full Text] [Related]  

  • 57. Role of small heat shock protein HSP25 in radioresistance and glutathione-redox cycle.
    Baek SH; Min JN; Park EM; Han MY; Lee YS; Lee YJ; Park YM
    J Cell Physiol; 2000 Apr; 183(1):100-7. PubMed ID: 10699971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced cellular glutathione levels do not affect the cytotoxicity or photocytotoxicity of the cationic photosensitiser Victoria Blue BO.
    Burrow SM; Phoenix DA; Wainwright M; Waring JJ
    Membr Cell Biol; 2000; 14(3):357-66. PubMed ID: 11368496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
    Osmak M
    Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.